Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Corey

Showing results (31-40 of 222) with videos related to

Pageof 23
Sort By:
The Prostate|October 21, 2014
Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenograftsVincent A DiPippo, William C Olson, Holly M Nguyen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 31, 2003
Characterization of C4-2 prostate cancer bone metastases and their response to castrationJesco Pfitzenmaier, Janna E Quinn, Austin M Odman, et al.
The Prostate|March 26, 2008
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acidTodd M Morgan, Tiffany E M Pitts, Ted S Gross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancerEva Corey, Lisha G Brown, Janna E Quinn, et al.
International Journal of Molecular Sciences|May 24, 2013
Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bonePeter S Kirk, Theodore Koreckij, Holly M Nguyen, et al.
Nutrients|December 31, 2025
The Olive Phenolic <i>S</i>-(-)-Oleocanthal as a Novel Intervention for Neuroendocrine Prostate Cancers: Therapeutic and Molecular InsightsMd Towhidul Islam Tarun, Hassan Y Ebrahim, Dalal Dawud, et al.
International Journal of Cancer|July 9, 2005
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancersAnton Stangelberger, Andrew V Schally, Markus Letsch, et al.
The Prostate|April 25, 2003
LuCaP 35: a new model of prostate cancer progression to androgen independenceEva Corey, Janna E Quinn, Kent R Buhler, et al.
International Journal of Cancer|April 3, 2003
Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexiaZejing Wang, Eva Corey, G Michael Hass, et al.
Nature Reviews. Urology|November 13, 2019
Radium-223 mechanism of action: implications for use in treatment combinationsMichael J Morris, Eva Corey, Theresa A Guise, et al.
Pageof 23

Showing results (31-40 of 222) with videos related to

Sort By:
Pageof 23
The Prostate|October 21, 2014
Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenograftsVincent A DiPippo, William C Olson, Holly M Nguyen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 31, 2003
Characterization of C4-2 prostate cancer bone metastases and their response to castrationJesco Pfitzenmaier, Janna E Quinn, Austin M Odman, et al.
The Prostate|March 26, 2008
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acidTodd M Morgan, Tiffany E M Pitts, Ted S Gross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancerEva Corey, Lisha G Brown, Janna E Quinn, et al.
International Journal of Molecular Sciences|May 24, 2013
Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bonePeter S Kirk, Theodore Koreckij, Holly M Nguyen, et al.
Nutrients|December 31, 2025
The Olive Phenolic <i>S</i>-(-)-Oleocanthal as a Novel Intervention for Neuroendocrine Prostate Cancers: Therapeutic and Molecular InsightsMd Towhidul Islam Tarun, Hassan Y Ebrahim, Dalal Dawud, et al.
International Journal of Cancer|July 9, 2005
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancersAnton Stangelberger, Andrew V Schally, Markus Letsch, et al.
The Prostate|April 25, 2003
LuCaP 35: a new model of prostate cancer progression to androgen independenceEva Corey, Janna E Quinn, Kent R Buhler, et al.
International Journal of Cancer|April 3, 2003
Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexiaZejing Wang, Eva Corey, G Michael Hass, et al.
Nature Reviews. Urology|November 13, 2019
Radium-223 mechanism of action: implications for use in treatment combinationsMichael J Morris, Eva Corey, Theresa A Guise, et al.
Pageof 23